Management of Dizziness in Patients with Severe Left Atrial Dilation

Initial Cardiac‑Specific Assessment

• The American College of Cardiology (ACC) advises that patients with severe left atrial dilation should be screened for atrial fibrillation, a highly prevalent arrhythmia that can produce dizziness through rapid ventricular response or hemodynamic instability. 1
• The ACC recommends measuring heart rate at rest and during activity because uncontrolled tachycardia is a common cause of dizziness in atrial fibrillation and warrants immediate rate‑control therapy. 3
• The ACC notes that severe left atrial dilation often coexists with left‑ventricular systolic or diastolic dysfunction; decompensated heart failure may manifest as dizziness and should be evaluated. 2

Immediate Rate‑Control Priorities

• For hemodynamically stable patients without heart‑failure, the ACC recommends intravenous β‑blockers (e.g., metoprolol 2.5–5 mg bolus) or nondihydropyridine calcium‑channel antagonists (e.g., diltiazem 0.25 mg/kg IV) to achieve rapid ventricular rate control. 4
• In patients with heart‑failure or left‑ventricular dysfunction, the ACC advises using intravenous digoxin or amiodarone, avoiding calcium‑channel blockers that may worsen hemodynamics. 2
• The European Society of Cardiology (ESC) supports an initial “lenient” rate‑control target of resting heart rate < 110 bpm, tightening the goal only if dizziness or other symptoms persist. 3
• Both the ACC and ESC caution against excessive bradycardia from rate‑control agents, as profound slowing can itself cause dizziness. 6

Anticoagulation Assessment

• The ACC states that all patients with atrial fibrillation and severe left atrial dilation should receive anticoagulation (target INR 2.0–3.0 for warfarin or guideline‑directed DOAC dosing) unless a contraindication exists. 7
• Ongoing therapeutic anticoagulation should be monitored regularly (e.g., monthly INR checks when stable) or ensured through adherence to DOAC regimens, per ACC guidance. 8

Medication Review

• Rate‑control drugs (β‑blockers, nondihydropyridine calcium‑channel blockers, digoxin) can precipitate excessive bradycardia or hypotension, contributing to dizziness; dose adjustment may be required. 5
• Antiarrhythmic agents such as amiodarone may prolong the QT interval and provoke additional arrhythmias, warranting careful ECG monitoring. 5

Long‑Term Rhythm‑vs‑Rate Strategies

• When a single rate‑control agent is insufficient, the ACC recommends combination therapy (digoxin plus a β‑blocker or a nondihydropyridine calcium‑channel blocker), with vigilant avoidance of bradycardia. 6
• For patients refractory to pharmacologic rate control or with tachycardia‑induced cardiomyopathy, the ACC suggests atrioventricular (AV) node ablation combined with permanent pacing. 6
• In severely symptomatic individuals with permanent atrial fibrillation, heart‑failure hospitalizations, and left atrial dilation, AV‑node ablation plus cardiac resynchronization therapy (CRT) reduces symptoms and mortality, according to ACC and ESC evidence. 2

Stroke‑Prevention Pitfalls

• The ACC warns against using calcium‑channel blockers in decompensated heart failure, as they can exacerbate hemodynamic compromise. 9
• Digoxin alone is ineffective for rate control during paroxysmal atrial fibrillation and should not be used as the sole agent, per ACC recommendations. 10
• Prompt initiation of anticoagulation is critical; delays increase stroke risk independent of other factors in patients with severe left atrial dilation. 7